Qiagen N.V. Logo

Qiagen N.V.

Provides 'Sample to Insight' solutions for molecular analysis in research and clinical healthcare.

QIA | F

Overview

Corporate Details

ISIN(s):
DE000A286LP0 (+5 more)
LEI:
54930036WK3GMCN17Z57
Country:
Netherlands
Address:
HULSTERWEG 82, 5912 PL VENLO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Qiagen N.V. is a leading global provider of integrated "Sample to Insight" solutions designed to enable customers to gain valuable molecular insights from biological samples. The company's comprehensive portfolio covers the entire molecular testing workflow, from sample preparation technologies that isolate DNA, RNA, and proteins, to assay technologies and automated instrumentation for analysis. Qiagen also provides bioinformatics software to interpret the resulting data. Its products are utilized by a diverse customer base across molecular diagnostics, academic research, pharmaceutical development, and applied testing, facilitating advancements in life sciences and clinical healthcare.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 00:00
Foreign Filer Report
Q3 statement / Q3 financial report 2025
English 896.5 KB
2025-11-04 19:02
Board/Management Information
QIAGEN N.V.: QIAGEN announces CEO transition plan
English 6.5 KB
2025-09-30 11:25
Interim / Quarterly Report
Qiagen N.V., Halfjaarlijkse financiële verslaggeving
English 268.3 KB
2025-08-28 07:57
Capital/Financing Update
QIAGEN N.V.: QIAGEN N.V. launches non-US offering of net share settled converti…
English 18.4 KB
2025-08-22 00:00
Foreign Filer Report
Half-yearly financial report 2025
English 428.1 KB
2025-05-13 00:00
Foreign Filer Report
Q1 statement / Q1 financial report 2025
English 693.8 KB
2025-05-07 14:35
Notice of Dividend Amount
QIAGEN N.V.: QIAGEN to propose initiation of annual cash dividend for sharehold…
English 6.8 KB
2025-04-28 16:33
Annual Report (ESEF)
Qiagen N.V., Jaarlijkse financiële verslaggeving
English 23.4 MB
2025-04-06 18:20
Earnings Release
QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates fu…
English 7.2 KB
2025-03-31 00:00
Annual Report
Annual financial report 2024
English 6.2 MB
2025-02-06 06:31
Earnings Release
QIAGEN delivers solid Q4 2024 growth ahead of outlook
English 478.9 KB
2025-01-13 18:55
Transaction in Own Shares
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
English 7.7 KB
2025-01-12 18:55
Share Issue/Capital Change
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
English 7.7 KB
2024-11-07 07:30
Earnings Release
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024…
English 421.6 KB
2024-09-03 09:01
Capital/Financing Update
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
English 56.8 KB

Automate Your Workflow. Get a real-time feed of all Qiagen N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Qiagen N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Qiagen N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-01 M. Colpan Non-Executive member Other 544 N/A
2022-02-28 T. Haag Non-Executive member Other 6,980 N/A
2022-02-21 R. Sackers Non-Executive member Other 43,200 N/A
2021-11-29 E.E. Tallett Non-Executive member Sell 1,563 87,051.28 USD
2021-11-29 E.E. Tallett Non-Executive member Buy 1,563 24,367.17 USD
2021-11-29 E.E. Tallett Non-Executive member Other 1,563 N/A
2021-11-26 R. Sackers Non-Executive member Sell 40,468 2,306,676.00 USD
2021-11-26 R. Sackers Non-Executive member Sell 200 11,402.00 USD
2021-10-31 R. Sackers Non-Executive member Other 76,749 N/A
2021-07-26 T. Bernard Non-Executive member Buy 2,000 102,940.00 USD

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Talk to a Data Expert

Have a question? We'll get back to you promptly.